Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Diagnostic markers for glioblastoma.

Literature DB >> 21870336

Diagnostic markers for glioblastoma.

Abstract

Glioblastoma (GBM) is the most malignant form of cerebral gliomas, and despite distinct progress in surgical resection, radiation and chemotherapy, the prognosis of patients with GBM is still very poor. In the past decades knowledge of genomics and proteomics and of diagnostic, prognostic, predictive and pharmakodynamic markers measured in cerebrospinal-fluid (CSF), serum, or tumor tissue biomarkers has improved. This review briefly compiles our concepts on diagnostic markers for GBM, focusing on the latest developments.

Entities: Disease Species

Mesh：

Substances：
Biomarkers, Tumor

Year: 2011 PMID： 21870336 DOI： 10.14670/HH-26.1327

Source DB: PubMed Journal: Histol Histopathol ISSN： 0213-3911 Impact factor: 2.303

Keyword Cloud
Cited

13 in total

1. Hsp27 (HSPB1): a possible surrogate molecular marker for loss of heterozygosity (LOH) of chromosome 1p in oligodendrogliomas but not in astrocytomas.

Authors: Gisela N Castro; Niubys Cayado-Gutiérrez; Vera L Moncalero; Patricia Lima; Rodolfo Lucero De Angelis; Victor Chávez; F Darío Cuello-Carrión; Daniel R Ciocca
Journal: Cell Stress Chaperones Date: 2012-07-18 Impact factor: 3.667

2. Prospective evaluation of serum glial fibrillary acidic protein (GFAP) as a diagnostic marker for glioblastoma.

Authors: Julia Tichy; Sabrina Spechtmeyer; Michel Mittelbronn; Elke Hattingen; Johannes Rieger; Christian Senft; Christian Foerch
Journal: J Neurooncol Date: 2015-10-30 Impact factor: 4.130

Review 3. Proteomic analysis of cerebrospinal fluid: toward the identification of biomarkers for gliomas.

Authors: Fang Shen; Yang Zhang; Yu Yao; Wei Hua; Hai-Shi Zhang; Jing-Song Wu; Ping Zhong; Liang-Fu Zhou
Journal: Neurosurg Rev Date: 2014-05-01 Impact factor: 3.042

4. A Genetically Modified Adenoviral Vector with a Phage Display-Derived Peptide Incorporated into Fiber Fibritin Chimera Prolongs Survival in Experimental Glioma.

Authors: Julius W Kim; J Robert Kane; Jacob S Young; Alan L Chang; Deepak Kanojia; Ramin A Morshed; Jason Miska; Atique U Ahmed; Irina V Balyasnikova; Yu Han; Lingjiao Zhang; David T Curiel; Maciej S Lesniak
Journal: Hum Gene Ther Date: 2015-08-11 Impact factor: 5.695

5. Addition of MR imaging features and genetic biomarkers strengthens glioblastoma survival prediction in TCGA patients.

Authors: Manal Nicolasjilwan; Ying Hu; Chunhua Yan; Daoud Meerzaman; Chad A Holder; David Gutman; Rajan Jain; Rivka Colen; Daniel L Rubin; Pascal O Zinn; Scott N Hwang; Prashant Raghavan; Dima A Hammoud; Lisa M Scarpace; Tom Mikkelsen; James Chen; Olivier Gevaert; Kenneth Buetow; John Freymann; Justin Kirby; Adam E Flanders; Max Wintermark
Journal: J Neuroradiol Date: 2014-07-02 Impact factor: 3.447

Diagnostic markers for glioblastoma.

1. Hsp27 (HSPB1): a possible surrogate molecular marker for loss of heterozygosity (LOH) of chromosome 1p in oligodendrogliomas but not in astrocytomas.

2. Prospective evaluation of serum glial fibrillary acidic protein (GFAP) as a diagnostic marker for glioblastoma.

Review 3. Proteomic analysis of cerebrospinal fluid: toward the identification of biomarkers for gliomas.

4. A Genetically Modified Adenoviral Vector with a Phage Display-Derived Peptide Incorporated into Fiber Fibritin Chimera Prolongs Survival in Experimental Glioma.

5. Addition of MR imaging features and genetic biomarkers strengthens glioblastoma survival prediction in TCGA patients.

6. The human secretome atlas initiative: implications in health and disease conditions.

7. Bridging the Brain and Data Sciences.

Review 8. Sudden, unexpected death due to glioblastoma: report of three fatal cases and review of the literature.

Review 9. Proteomic approaches in biomarker discovery: new perspectives in cancer diagnostics.

Review 10. Advances in the proteomic discovery of novel therapeutic targets in cancer.